You are here

Plans for a Phase 3 Study of PV-10 in Melanoma

Robert Andtbacka of the University of Utah discusses plans for a phase 3 trial involving PV-10 in patients with stage 3b and 3c melanoma who have failed or were not candidates for immunotherapy and patients who are BRAF-negative: Patients who currently don’t have good treatment options.

11th International Congress of the Society for Melanoma Research, November 2014